trial

Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia

NCTId NCT00999505
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Unknown
Enrollment 40 (estimated)
Sponsored by Hospital de Clinicas de Porto Alegre
Primary completion 2011-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Unknown
Enrollment
40 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2010-05
Primary completion
2011-09
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
amantadine

Sponsors

Hospital de Clinicas de Porto AlegreLead Sponsor

Investigators

1
Clarissa S Gama, MD, PhDPrincipal Investigator

Sites

1 total
Porto Alegre, Brazil

Linked catalysts

1
Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia — primary completion2011-09

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE3
Primary Completion Date
2011-09
Status
UNKNOWN
relationships
The graph out of here
drug
amantadine
drug
lead_sponsor
Hospital de Clinicas de Porto Alegre
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Clarissa S Gama, MD, PhD
person